annual report & insulin launch
Recent activity wtih scigen has centred on commercialisation deals with China re: its hep B vaccine. Shouldn't overlook fact that company has a number of products including Scilin (a second-generation recombinant human insulin - used for the treatment of diabetes). Scigen has already executed commercialisation agreements for the major markets in the Indian Sub-Continent (India, Pakistan, Bangladesh and Sri Lanka).
In their recent annual report the company wrote "health registration achieved in Philipines" and importantly that product launch is expected in November 2005.
One to watch...
Pol
SIE Price at posting:
0.0¢ Sentiment: None Disclosure: Held
